GRAPHIC APPAREL SHOPWhat if we could develop new life saving medicines in months instead of years. Lilly partnerig with NVIDIA to turn this vision into reality by launching the pharmaceutical industry's largest AI factory, powered by over 1,000 NVIDIA Blackwell Ultra GPUs and the cutting-edge DGX SuperPOD.
Announced at NVIDIA GTC Washington, D.C., this groundbreaking initiative signals a new era of computational capacity and ambition, poised to transform genomics, personalized medicine, and molecular design on an unprecedented scale.
Revolutionary AI Models and Collaborative Learning
At the heart of Lilly’s AI factory are advanced biomedical foundation and frontier models designed for drug discovery. Supported by $1 billion in proprietary data and leveraging both Lilly’s in-house models and NVIDIA Clara’s open-source healthcare models, these AI systems drive innovation via Lilly’s TuneLab platform.
Built on NVIDIA FLARE, TuneLab enables federated learning, allowing biotech partners to benefit from powerful AI insights while keeping their data private. This collaborative approach ensures that as more users join, the models continue to improve, fostering a cycle of shared progress.
Unlocking New Scientific Possibilities
According to Thomas Fuchs, Lilly’s chief AI officer, these foundation models are revealing novel chemical possibilities unreachable by traditional methods. By merging scientific expertise with accelerated technology, Lilly is not just experimenting but building scalable solutions that could deliver breakthrough treatments to millions worldwide.
AI Across the Drug Development Pipeline
Lilly’s AI factory brings transformative power to every stage of drug development:
- Genomics: Rapid analysis of entire genome sequences for deep biological insights.
- Predictive Modeling: Forecasting patient outcomes and exploring a vast landscape of biochemical scenarios.
- Antibody and Molecule Generation: Utilizing NVIDIA BioNeMo to process data from millions of experiments, rapidly designing and testing new therapeutic candidates.
- Precision Medicine: Employing deep learning frameworks like MONAI to speed up imaging analysis and tailor treatments to individual patients.
- Clinical Operations: Streamlining documentation and automating workflows in clinical trials with advanced language models.
Reinventing Biomanufacturing with Digital Twins and Robotics
Lilly’s AI innovation extends into manufacturing. Using NVIDIA Omniverse and RTX PRO Servers, the company creates digital twins of production lines for virtual modeling, stress-testing, and optimization before real-world implementation. Robotics powered by NVIDIA Isaac improve efficiency, managing quality inspections and material transport to reduce downtime and boost productivity.
AI agents built with NVIDIA NeMo work tirelessly across both digital and real-world labs, generating hypotheses, designing novel treatments, and simulating experiments. This synergy not only enhances productivity but also fosters scientific creativity, supporting Lilly’s mission to advance both human and machine intelligence.
Economic Impact and U.S. Leadership
Lilly’s investment in AI does more than accelerate medical innovation—it also drives economic growth. The company’s expansion, including a $4.5 billion facility in Indiana, is expected to create over 13,000 high-wage jobs. The AI factory’s computational might is staggering: a single Blackwell Ultra GPU matches the power of 7 million Cray supercomputers, and with 1,016 GPUs, Lilly achieves over 9,000 petaflops—enabling solutions to 9 quintillion math problems per second.
Recognized by CB Insights as the most AI-ready pharma company, Lilly’s partnership with NVIDIA cements its place as a global AI-native leader. Their efforts are not only accelerating drug development but also reinforcing America’s leadership in advanced manufacturing and highly regulated industries.
Pioneering the Future of Healthcare
Lilly’s collaboration with NVIDIA marks a transformative shift in how medicines are discovered, developed, and manufactured. With the world’s most powerful AI-driven drug discovery platform, Lilly is setting new industry standards and bringing faster, more personalized treatments to patients worldwide.
Lilly’s AI Factory Is Accelerating the Future of Drug Discovery with NVIDIA Blackwell and DGX SuperPOD